Author:
Waqar Saiama N,Morgensztern Daniel
Reference10 articles.
1. ALK in lung cancer: past, present, and future;Shaw;J Clin Oncol,2013
2. First-line crizotinib versus chemotherapy in ALK-positive lung cancer;Solomon;N Engl J Med,2014
3. Anaplastic lymphoma kinase as a therapeutic target in non-small cell lung cancer;Iams;Cancer J,2015
4. molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer;Gainor;Cancer Discov,2016
5. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial;Shaw;Lancet Oncology,2017
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献